BIOMEDICA MANAGEMENT CORP.

Basic Information

760 Parkside Ave., #304
BROOKLYN, NY, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 146587345
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 7


  1. Clinical Development of Hemostatic Agent ClotFoam for Severe Hemorrhage

    Amount: $1,977,696.00

    DESCRIPTION (provided by applicant): ClotFoam(R) , is a novel adhesive sealant composition and second-generation hemostatic agent. This biological agent was designed to arrest moderate to severe bl ...

    SBIR Phase II 2012 Department of Health and Human Services
  2. Clinical Development of Hemostatic Agent ClotFoam for Severe Hemorrhage

    Amount: $1,001,006.00

    DESCRIPTION (provided by applicant): Hemorrhage resulting from traumatic injuries is a major cause of death in accidents, and the primary cause of death on the battlefield. Over 40% of the trauma case ...

    SBIR Phase II 2009 Department of Health and Human Services
  3. non-compressible Biodegradable Hemostatic Agent

    Amount: $69,998.00

    we propose to determine the biocompatibility of ClotFoam and enhance its hemostastic and non-compressible sealing effects against a severe parenchymial hemorrhage caused by a wound grade V affecting m ...

    SBIR Phase I 2009 ArmyDepartment of DefenseDepartment of Defense
  4. Immunomodulation of Sophorolipids in Sepsis

    Amount: $99,999.00

    DESCRIPTION (provided by applicant): Microbial sophrolipids are a new a class of membrane-derived glycolipids that have wide ranging potential in clinical practice. We have demonstrated that sophoroli ...

    SBIR Phase I 2008 Department of Health and Human Services
  5. Tissue Sealant for Intracavitary Non-compressible Hemorrhage

    Amount: $98,957.00

    ClotFoam is a novel crosslinked polymer designed to stop hemorrhage without compression in severe wounds outside the operating room. ClotFoam's ability to promote hemostasis in cases severe bleeding i ...

    SBIR Phase I 2008 Defense Advanced Research Projects AgencyDepartment of DefenseDepartment of Defense
  6. Anti-ischemic Resuscitation Fluid

    Amount: $104,178.00

    DESCRIPTION (provided by applicant): Inflammation after ischemia and reperfusion (I/R) injury secondary to hemorrhagic shock is responsible for significant mortality and morbidity in the United States ...

    SBIR Phase I 2007 Department of Health and Human Services
  7. Intracavitary Hemostatic Agent for Non-compressible Hemorrhage

    Amount: $103,148.00

    DESCRIPTION (provided by applicant): Hemorrhage resulting from traumatic injuries is a major cause of death in accidents, and the primary cause of death on the battlefield. Early and effective hemorrh ...

    SBIR Phase I 2007 Department of Health and Human Services
  8. Anti-Selectin Blocker for Liver Ischemic Injury

    Amount: $719,044.00

    DESCRIPTION (provided by applicant): Our objective is to develop a new treatment that will prevent or decrease the tissue damage caused by neutrophil infiltration after ischemia/reperfusion (I/R), ...

    SBIR Phase II 2004 Department of Health and Human Services
  9. ANTI-SELECTIN BLOCKER FOR ORGAN ISCHEMIC INJURY

    Amount: $107,000.00

    Description (provided by applicant): Drugs currently available for the treatment of ischemic (lack of blood supply) conditions are not satisfactory. Since selectins have a primordial role in the devel ...

    SBIR Phase I 2002 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government